Название продукции:1-(5-Bromo-1H-indazol-3-yl)ethanone

IUPAC Name:1-(5-bromo-1H-indazol-3-yl)ethan-1-one

CAS:886363-74-2
Молекулярная формула:C9H7BrN2O
Чистота:95%
Номер в каталоге:CM231240
Молекулярная масса:239.07

Упаковочная единица Доступно для заказа Цена ($) Количество
CM231240-250mg in stock ǵƓ
CM231240-1g in stock ŗǵƥ
CM231240-5g in stock ʼnĽʼn

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:886363-74-2
Молекулярная формула:C9H7BrN2O
Точка плавления:-
Smiles-код:CC(C1=NNC2=C1C=C(Br)C=C2)=O
Плотность:
Номер в каталоге:CM231240
Молекулярная масса:239.07
Точка кипения:403.8±25.0°C at 760 mmHg
Номер Mdl:MFCD07374362
Хранение:Keep in a tight container and store at 2°C~8°C,protect from light

Category Infos

Indazoles
Indazoles are a class of organic heterocyclic compounds, also known as 1,2-diazaindene and benzopyrazole. Indazole is a good bioisomer of phenol, which is more lipophilic than phenol and less prone to phase I and II metabolism. Indazole derivatives have a wide range of biological activities, and it has been confirmed that indazole compounds have anti-tumor, analgesic, anti-inflammatory and other drug activities. Anticancer is the most important application field of indazole drugs. Renal cell carcinoma, solid tumor, nausea and vomiting caused by chemotherapy and leukemia are the main indications of this structural backbone drug.

Column Infos

Voydeya
Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). Voydeya is the first drug in the class to be cleared for marketing anywhere in the world and has been licensed for use as an add-on therapy to C5 inhibitors, like its own Soliris (eculizumab) and Ultomiris (ravulizumab) products, in patients who don’t get a satisfactory response from C5 drugs alone. Voydeya (danicopan) is a first-in-class oral Factor D inhibitor. Voydeya has been granted Breakthrough Therapy designation by the US Food and Drug Administration and PRIority MEdicines (PRIME) status by the European Medicines Agency. Voydeya has also been granted Orphan Drug Designation in the US, EU and Japan for the treatment of PNH.

Related Products